AR088925A1 - Derivados de 3-cianaril-1h-pirrolo[2,3-b]piridina - Google Patents

Derivados de 3-cianaril-1h-pirrolo[2,3-b]piridina

Info

Publication number
AR088925A1
AR088925A1 ARP120104361A ARP120104361A AR088925A1 AR 088925 A1 AR088925 A1 AR 088925A1 AR P120104361 A ARP120104361 A AR P120104361A AR P120104361 A ARP120104361 A AR P120104361A AR 088925 A1 AR088925 A1 AR 088925A1
Authority
AR
Argentina
Prior art keywords
phet1
hal
nhcoo
nhconh
atoms
Prior art date
Application number
ARP120104361A
Other languages
English (en)
Inventor
Dr Dipl-Chem Dorsch Dieter
Dr Hoelzemann Guenter
Dr Eggenweiler Hans
Michael-Dr Czodrowski Paul
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of AR088925A1 publication Critical patent/AR088925A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Los compuestos de la fórmula (1) en donde X es CH o N; R¹ es H, A o Cyc; R² es O[C(R⁶)₂]ₙHet¹, NR⁶[C(R⁶)₂]ₙHet¹, O[C(R⁶)₂]ₙCyc o NR⁶[C(R⁶)₂]ₙCyc; R³ es H, Hal, A, OR⁶, N(R⁶)₂, O[C(R⁶)₂]ₘN(R⁶)₂, O[C(R⁶)₂]ₙHet², NR⁶[C(R⁶)₂]ₘN(R⁶)₂, NR⁶[C(R⁶)₂]ₙHet², Ar o Het²; R⁴ es H u OR⁶; R⁵ es H u OR⁶; R⁶ es H o alquilo C₁₋₆ no ramificado o ramificado, en donde 1 - 7 átomos de H pueden estar reemplazados por F; Het¹ es dihidropirrolilo, pirrolidinilo, azetidinilo, oxetanilo, tetrahidroimidazolilo, dihidropirazolilo, tetrahidropirazolilo, tetrahidrofuranilo, dihidropiridilo, tetrahidropiridilo, piperidinilo, morfolinilo, hexahidropiridazinilo, hexahidropirimidinilo, [1,3]dioxolanilo, tetrahidropiranilo o piperazinilo no sustituido o monosustituido con Hal, CN, OH, OA, COOA, CONH₂, S(O)ₙA, S(O)ₙAr, COA, A u =O; Het² es dihidropirrolilo, pirrolidinilo, azetidinilo, tetrahidroimidazolilo, tetrahidrofuranilo, dihidropirazolilo, tetrahidropirazolilo, dihidropiridilo, tetrahidropiridilo, dihidropiranilo, tetrahidropiranilo, piperidinilo, morfolinilo, hexahidropiridazinilo, hexahidropirimidinilo, [1,3]dioxolanilo, piperazinilo, furilo, tienilo, pirrolilo, imidazolilo, pirazolilo, oxazolilo, isoxazolilo, tiazolilo, triazolilo, tetrazolilo, piridilo, pirimidilo, piridazinilo, indolilo, isoindolilo, bencimidazolilo, indazolilo, quinolilo, 1,3-benzodioxolilo, benzotiofenilo, benzofuranilo, imidazopiridilo o furo[3,2-b]piridilo no sustituido o mono- o disustituido con Hal, A, [C(R⁶)₂]ₚOR⁶, [C(R⁶)₂]ₚN(R⁶)₂, [C(R⁶)₂]ₚHet¹, NO₂, CN, [C(R⁶)₂]ₚCOOR⁶, CON(R⁶)₂, NR⁶COA, NR⁶SO₂A, SO₂N(R⁶)₂, S(O)ₙA, COHet¹, O[C(R⁶)₂]ₚN(R⁶)₂, O[C(R⁶)₂]ₚHet¹, NHCOOA, NHCON(R⁶)₂, NHCOO[C(R⁶)₂]ₚN(R⁶)₂, NHCOO[C(R⁶)₂]ₚHet¹, NHCONH[C(R⁶)₂]ₚN(R⁶)₂, NHCONH[C(R⁶)₂]ₚHet¹, OCONH[C(R⁶)₂]ₚN(R⁶)₂, OCONH[C(R⁶)₂]ₚHet¹, CHO, COA, =S, =NR⁶ y/u =O; Ar es fenilo o naftilo no sustituido o mono-, disustituido o trisustituido con Hal, A, [C(R⁶)₂]ₚOR⁶, [C(R⁶)₂]ₚN(R⁶)₂, [C(R⁶)₂]ₚHet¹, NO₂, CN, [C(R⁶)₂]ₚCOOR⁶, CON(R⁶)₂, NR⁶COA, NR⁶SO₂A, SO₂N(R⁶)₂, S(O)ₙA, COHet¹, O[C(R⁶)₂]ₚN(R⁶)₂, O[C(R⁶)₂]ₚHet¹, NHCOOA, NHCON(R⁶)₂, NHCOO[C(R⁶)₂]ₚN(R⁶)₂, NHCOO[C(R⁶)₂]ₚHet¹, NHCONH[C(R⁶)₂]ₚN(R⁶)₂, NHCONH[C(R⁶)₂]ₚHet¹, OCONH[C(R⁶)₂]ₚN(R⁶)₂, OCO-H[C(R⁶)₂]ₚHet¹, CHO y/o COA; A es alquilo C₁₋₁₀ no ramificado o ramificado, en donde uno o dos grupos CH y/o CH₂ no adyacentes pueden estar reemplazados por átomos de N, O y/o S y/o también 1 - 7 átomos de H pueden estar reemplazados por F y/o Cl; Cyc es alquilo cíclico no sustituido o monosustituido con CN o sustituido con A con 3, 4, 5, 6 o 7 átomos de C; Hal es F, Cl, Br o I; m es 1, 2 ó 3; n es 0, 1 ó 2; p es 0, 1, 2, 3 ó 4; así como sus sales, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones. Son inhibidores de TBK1 e IKKe y se pueden usar, por ejemplo, para el tratamiento de cáncer y enfermedades inflamatorias.
ARP120104361A 2011-11-22 2012-11-21 Derivados de 3-cianaril-1h-pirrolo[2,3-b]piridina AR088925A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102011119127A DE102011119127A1 (de) 2011-11-22 2011-11-22 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate

Publications (1)

Publication Number Publication Date
AR088925A1 true AR088925A1 (es) 2014-07-16

Family

ID=47115757

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104361A AR088925A1 (es) 2011-11-22 2012-11-21 Derivados de 3-cianaril-1h-pirrolo[2,3-b]piridina

Country Status (11)

Country Link
US (1) US9102675B2 (es)
EP (1) EP2794602B1 (es)
JP (1) JP6096797B2 (es)
CN (1) CN103946223B (es)
AR (1) AR088925A1 (es)
AU (1) AU2012342891B2 (es)
CA (1) CA2856357C (es)
DE (1) DE102011119127A1 (es)
ES (1) ES2661256T3 (es)
IL (1) IL232717B (es)
WO (1) WO2013075785A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
TW201613916A (en) * 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
CN106715419A (zh) 2014-09-26 2017-05-24 吉利德科学公司 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物
WO2017003995A1 (en) * 2015-06-29 2017-01-05 Merck Patent Gmbh TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF
CA3006772A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
CA3136224A1 (en) * 2019-04-09 2020-10-15 Plexxikon Inc. Condensed azines for ep300 or cbp modulation and indications therefor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
EP2332940B1 (en) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
CA2573362A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
TW200804386A (en) * 2005-11-10 2008-01-16 Schering Corp Imidazopyrazines as protein kinase inhibitors
CN101484452A (zh) 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
EA200901157A1 (ru) * 2007-04-10 2010-04-30 ЭсДжиИкс ФАРМАСЬЮТИКАЛЗ, ИНК. Конденсированные кольцевые гетероциклические модуляторы киназы
WO2009030890A1 (en) 2007-09-03 2009-03-12 University Court Of The University Of Dundee Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
CA2703125C (en) 2007-10-25 2012-08-28 David J. Guerin Pyrazinyl-substituted pyrrolo[2,3-b]pyridines, compositions thereof, and their use in the treatment of cancer
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
GB0903759D0 (en) 2009-03-04 2009-04-15 Medical Res Council Compound
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
CA2777762A1 (en) 2009-10-12 2011-04-21 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon

Also Published As

Publication number Publication date
EP2794602B1 (de) 2017-11-29
CA2856357C (en) 2019-10-01
US9102675B2 (en) 2015-08-11
IL232717A0 (en) 2014-08-03
DE102011119127A1 (de) 2013-05-23
CN103946223A (zh) 2014-07-23
US20140323481A1 (en) 2014-10-30
IL232717B (en) 2018-08-30
WO2013075785A1 (de) 2013-05-30
CA2856357A1 (en) 2013-05-30
CN103946223B (zh) 2017-01-18
EP2794602A1 (de) 2014-10-29
JP6096797B2 (ja) 2017-03-15
ES2661256T3 (es) 2018-03-28
AU2012342891A1 (en) 2014-07-03
AU2012342891B2 (en) 2016-10-13
AU2012342891A8 (en) 2014-07-31
JP2014534246A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
AR088925A1 (es) Derivados de 3-cianaril-1h-pirrolo[2,3-b]piridina
AR087807A1 (es) Derivados de benzonitrilo
AR094981A1 (es) Derivados de imidazopirimidinas
AR090240A1 (es) Derivados de triazolopirazina
AR089810A1 (es) Derivados de triazolo[4,5-d]pirimidina
AR090896A1 (es) DERIVADOS DE PIRROLOTRIAZINONA COMO INHIBIDORES DE TANKs Y PARP-1
AR090496A1 (es) Derivados biciclicos de pirazinona
AR094982A1 (es) Derivados de triazolo[4,5-d]pirimidina
AR089945A1 (es) DERIVADOS DE FURO[3,2-B] Y TIENO[3,2-B]PIRIDINA COMO MODULADORES DE TBK1 E IKKe
AR092366A1 (es) Derivados de (aza-)isoquinolinona
AR093512A1 (es) Derivados heterociclicos como moduladores de la actividad de cinasas
AR090602A1 (es) AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2
AR096149A1 (es) Macrociclos como inhibidores de quinasa
AR066543A1 (es) Derivados de piridazinona
AR092365A1 (es) Derivados de piridopirimidina
AR093017A1 (es) MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO
AR071208A1 (es) Derivados de piridazinona
AR085110A1 (es) Derivados de 7-azaindol
AR072860A1 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina
AR073055A1 (es) Derivados biciclicos de triazol
AR092211A1 (es) Derivados de hidropirrolopirrol
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR067081A1 (es) Derivados de pirrolo[2,3-b]piridin-pirimidina,proceso de preparacion, medicamentos que los contienen y usos de los mismos para el tratamiento de tumores cancerigenos y metastasis tumorales.
AR082574A1 (es) Compuestos de 1,4,5,6-tetrahidro-pirimidin-2-ilamina, composiciones farmaceuticas en base al compuesto y procedimiento para la obtencion del compuesto
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FC Refusal